Skip to main content
. Author manuscript; available in PMC: 2018 Aug 13.
Published in final edited form as: Expert Rev Mol Diagn. 2018 Jan 16;18(2):155–163. doi: 10.1080/14737159.2018.1427068

Table 5.

Potential predictive biomarkers under investigation for mCRPC therapy-selection.

Potential Predictive Biomarker Therapy Selection
AR-V7 31,32,34,64 Not detected: ARS inhibitors
Detected: taxane chemotherapy
Activating AR-LBD mutations and/or AR gene amplification65,66 Not detected: ARS inhibitors
Detected: taxane chemotherapy
CTC heterogeneity67 (Shannon index) Low (Shannon <1.5): TARS inhibitors
High (Shannon ≥1.5): taxane chemotherapy
DDR gene alterations PARP inhibitors68 or platinum agents69
Microsatellite instability (MSI-high) Immunotherapy with anti-PD-1 (pembrolizumab)70

Abbreviations: ARS: androgen receptor signaling; AR-V7: androgen receptor splice variant 7; AR-LBD: androgen receptor ligand-binding domain; CTC: circulating tumor cell; DDR: DNA damage repair; PARP: poly ADP (adenosine diphosphate)-ribose polymerase; PD-1 programmed death.